Product image of Letrozol Tecnigen (Letrozole) supplied by GNH India

Letrozol Tecnigen

Active Ingredient:
Letrozole
Origin:
EU

Letrozol Tecnigen (Letrozole)

Letrozole, the active ingredient in Letrozol Tecnigen, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women. The drug works by blocking estrogen synthesis, thereby limiting tumor growth driven by estrogen signaling.

GNH India supplies Letrozol Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to EU quality standards and provides regulatory documentation to facilitate import and distribution in multiple markets.

Manufacturer / TM Owner

Tecnimede España Ind. Fca., S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Letrozole is an aromatase inhibitor used in hormone‑dependent breast cancer management.

  • Adjuvant therapy: reduces risk of cancer recurrence after surgery in postmenopausal women with hormone receptor‑positive breast cancer.
  • Metastatic disease: slows disease progression and improves survival in patients with advanced hormone receptor‑positive breast cancer.
  • Neoadjuvant therapy: may shrink tumors before surgery, facilitating breast‑conserving procedures in eligible postmenopausal patients.

How It Works

  • Letrozole reversibly binds to the aromatase enzyme (CYP19A1) in peripheral tissues, inhibiting the conversion of androstenedione and testosterone into estrone and estradiol. By lowering circulating estrogen levels, the drug deprives estrogen‑dependent tumor cells of a growth stimulus, leading to reduced proliferation and possible tumor regression in hormone receptor‑positive breast cancer. The inhibition is dose‑dependent and persists for several days after the last dose, allowing sustained estrogen suppression.

Side Effects

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Hot flashes: transient feeling of warmth and sweating.
  • Joint and muscle pain: arthralgia or myalgia affecting daily activities.
  • Fatigue: persistent tiredness not relieved by rest.
  • Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects

  • Severe osteoporosis: increased risk of bone fractures requiring monitoring.
  • Cardiovascular events: rare cases of myocardial infarction or stroke.
  • Liver dysfunction: elevated transaminases or hepatitis.

Precautions & Warnings

When prescribing Letrozole, clinicians should consider several safety measures to minimize risks.

  • Assess bone health: perform baseline densitometry and consider calcium/vitamin D supplementation.
  • Monitor liver function: check transaminases periodically during therapy.
  • Evaluate cardiovascular risk: review history of thromboembolic disease before initiation.
  • Avoid use in premenopausal women: drug is ineffective without ovarian suppression.
  • Inform patients about potential hot flashes and joint pain and advise reporting severe symptoms.
  • Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Avoid Interactions

Letrozole can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce plasma levels of letrozole.
  • Tamoxifen: concurrent use can antagonize aromatase inhibition and affect therapeutic outcome.
  • Estrogen‑containing hormone therapy: opposes the intended estrogen‑lowering effect.

Moderate Interactions (Monitor Closely)

  • Warfarin: letrozole may enhance anticoagulant effect, requiring INR monitoring.
  • Selective serotonin reuptake inhibitors (SSRIs): may increase risk of bone loss.
  • Glucocorticoids: additive effect on bone density reduction.

Frequently Asked Questions

Letrozol Tecnigen contains letrozole, an aromatase inhibitor indicated for the treatment of hormone receptor‑positive breast cancer in postmenopausal women. It is used in adjuvant, neoadjuvant and metastatic settings to reduce estrogen‑driven tumor growth.

Letrozole blocks the aromatase enzyme, which converts androgens into estrogens in peripheral tissues. By suppressing estrogen production, the drug lowers circulating estrogen levels, depriving estrogen‑dependent breast cancer cells of a key growth signal.

The dosage of Letrozol Tecnigen is determined by the prescribing clinician based on the patient’s clinical condition, treatment setting and individual factors. Specific dosing regimens are not disclosed here and should follow the prescriber’s order and local labeling.

Letrozole is classified as contraindicated in pregnancy because it can interfere with fetal development. It is also not recommended during breastfeeding, as it may pass into breast milk and affect the infant. Women of child‑bearing potential should use effective contraception.

To order Letrozol Tecnigen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Letrozol Tecnigen (letrozole) is a third‑generation aromatase inhibitor with a long half‑life and potent estrogen suppression, similar to anastrozole and exemestane. Compared with anastrozole, letrozole often provides slightly greater estrogen reduction, while exemestane is a steroidal inhibitor with a different safety profile.

Letrozol Tecnigen should be stored at ambient temperature below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and store them out of reach of children.

Letrozol Tecnigen is taken orally, usually as a single tablet per day, with or without food. The exact administration schedule is determined by the treating physician and should follow the prescribed instructions.

Serious risks include severe osteoporosis leading to fractures, rare cardiovascular events such as myocardial infarction or stroke, and significant liver dysfunction. Patients should be monitored regularly for bone density, liver enzymes and cardiovascular health.

Letrozol Tecnigen should not be used in premenopausal women, pregnant or nursing mothers, and individuals with known hypersensitivity to letrozole or any excipients. Caution is also advised for patients with uncontrolled liver disease or severe osteoporosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT